We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Medigen Vaccine Biologics Corp (MVC) vaccine candidate, MVC-COV1901, has been recommended by an independent vaccine prioritisation advisory group to be included in the World Health Organisation (WHO) Solidarity Trial Vaccines (STv).
Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation today announced the rollout of its COVID-19 vaccine, MVC-COV1901. Approximately 600,000 people are anticipated to receive the Medigen vaccine this week.
Medigen Vaccine Biologics (MVC) and Dynavax Technologies announced the first participant has been dosed in the Phase 2 clinical trial evaluating MVC's COVID-19 vaccine candidate, MVC-COV1901.
Medigen Vaccine Biologics and Dynavax Technologies announced that MVC has obtained a China's Taiwan, China government subsidy for successfully initiating a Phase 1 clinical trial in Taiwan, China.